» Articles » PMID: 30539520

Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid

Overview
Specialty Oncology
Date 2018 Dec 13
PMID 30539520
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

To observe the expression of P53, CyclinD1, Ki-67, Galectin-3, COX-2, Bcl-2 and approach their contribution on assessing the invasive potential for Hurthle cell tumors. Seventy-three cases of Hurthle cell tumor were collected for immunohistochemistry staining. The patients were followed up with 8 months to 5 years. Tumors were divided into four grades according to invasion and diameter:(1) extremely low risk (27 cases that less than 2 cm and without invasion), (2) low risk (18 cases that within 2-3.9 cm and without invasion), (3) moderate risk (21 cases that achieve 4 cm and without invasion), (4) high risk (7 cases that with invasion of capsule/vessel in spite of the diameter). Immunostaining presented that all 73 cases were positive with Galectin-3, COX-2 and Bcl-2. For each group, P53 positive were 29.6%, 55.6%, 90.5%, 100.0%; CyclinD1 stained with 7.4%,22.2%,52.4%,100.0% and Ki-67 were 0.0%,5.6%,9.5%,28.6%, respectively. The higher risk of tumor, the more cases that positive expressed P53 and CyclinD1. After following up within 49 patients, two of the recurring cases were positive with P53 and CyclinD1 and one of which was also highly expressed Ki-67. Detecting P53, CyclinD1 and Ki-67 might provide reference for invasive potential assessment with Hurthle cell tumors but not Galectin-3, COX-2 and Bcl-2.

Citing Articles

Oncocytic Hyperplastic Nodule Versus Oncocytic Adenoma: Diagnostic Controversies Through a Brief Investigative Case Series Study.

Topalidis C, Petrakis G, Koletsa T Cureus. 2024; 16(5):e60361.

PMID: 38882980 PMC: 11178239. DOI: 10.7759/cureus.60361.


Thyroid Hürthle Cell Carcinoma: Clinical, Pathological, and Molecular Features.

Kure S, Ohashi R Cancers (Basel). 2020; 13(1).

PMID: 33374707 PMC: 7793513. DOI: 10.3390/cancers13010026.

References
1.
Erickson L, Jin L, Goellner J, Lohse C, Pankratz V, Zukerberg L . Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol. 2000; 13(2):186-92. DOI: 10.1038/modpathol.3880034. View

2.
Sugino K, Mimura T, Kameyama K, Iwasaki H, Ito K . Hürthle cell tumor of the thyroid: analysis of 188 cases. World J Surg. 2001; 25(9):1160-3. DOI: 10.1007/BF03215865. View

3.
Hoos A, Stojadinovic A, Singh B, Dudas M, Leung D, Shaha A . Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol. 2002; 160(1):175-83. PMC: 1867123. DOI: 10.1016/S0002-9440(10)64361-1. View

4.
Chao T, Lin J, Chen M . Surgical treatment of Hurthle cell tumors of the thyroid. World J Surg. 2005; 29(2):164-8. DOI: 10.1007/s00268-004-7669-9. View

5.
Besic N, Hocevar M, Zgajnar J, Petric R, Pilko G . Aggressiveness of therapy and prognosis of patients with Hürthle cell papillary thyroid carcinoma. Thyroid. 2006; 16(1):67-72. DOI: 10.1089/thy.2006.16.67. View